Tumor-Educated Extracellular Vesicle-Derived LINC01116 Drives Non-Small Cell Lung Cancer Progression and Immunosuppression by Sponging miR-3614-5p to Upregulate ARHGAP1
International Immunopharmacology · 2026
DOI: 10.1016/j.intimp.2026.116347 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2026. Verfasst von Hongwei Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rehabilitation Medicine, The Affiliated Yongchuan Hospital of Chongqing Medical University, Chongqing 402160, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, MicroRNAs, GTPase-Activating Proteins, Lung Neoplasms. Die Arbeit nennt 48 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVE: To investigate the role of extracellular vesicle (EV)-derived long non-coding RNA (lncRNA) in non-small cell lung cancer (NSCLC) progression and the tumor immune microenvironment. METHODS: Bioinformatic analyses of TCGA data identified an eight-lncRNA prognostic signature, including LINC01116. A LINC01116-centered ceRNA network was constructed. EVs from NSCLC patient blood were isolated. Functional effects were assessed using in vitro proliferation, migration, invasion, and macrophage polarization assays, and in vivo mouse models. Molecular interactions were validated by RNA pull-down, RIP, and luciferase assays. RESULTS: LINC01116 was upregulated in NSCLC tissues and EVs. It functioned as a ceRNA by sponging miR-3614-5p, leading to upregulation of ARHGAP1. Single-cell RNA-seq revealed LINC01116 expression in epithelial cells and macrophages. EV-transferred LINC01116 promoted NSCLC cell malignancy, induced macrophage M2 polarization, and accelerated tumor growth and metastasis in vivo via the miR-3614-5p/ARHGAP1 axis. CONCLUSION: EV-derived LINC01116 promotes NSCLC progression and immunosuppression via the miR-3614-5p/ARHGAP1 pathway, presenting a novel prognostic and therapeutic target.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Rehabilitation Medicine, The Affiliated Yongchuan Hospital of Chongqing Medical University, Chongqing 402160, China.
- Department of Medical Laboratory, The Affiliated Yongchuan Hospital of Chongqing Medical University, Chongqing 402160, China.
- Department of Neurology, The Affiliated Yongchuan Hospital of Chongqing Medical University, Chongqing 402160, China.
- Department of Cardiothoracic Surgery, The Affiliated Yongchuan Hospital of Chongqing Medical University, Chongqing 402160, China. Electronic address: gninoam@163.com.
- Department of Neurology, The Affiliated Yongchuan Hospital of Chongqing Medical University, Chongqing 402160, China. Electronic address: yangzhao5140@sohu.com.
Zitieren
APA
Zhang, H., Hou, Y., Wang, Y., Zhang, M., Mao, N., & Yang, Z. (2026). Tumor-Educated Extracellular Vesicle-Derived LINC01116 Drives Non-Small Cell Lung Cancer Progression and Immunosuppression by Sponging miR-3614-5p to Upregulate ARHGAP1. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2026.116347
Vancouver
Zhang H, Hou Y, Wang Y, Zhang M, Mao N, Yang Z. Tumor-Educated Extracellular Vesicle-Derived LINC01116 Drives Non-Small Cell Lung Cancer Progression and Immunosuppression by Sponging miR-3614-5p to Upregulate ARHGAP1. International Immunopharmacology. 2026. doi:10.1016/j.intimp.2026.116347
BibTeX
@article{Zhang2026,
author = {Zhang, Hongwei and Hou, Yongbin and Wang, Yuanjie and Zhang, Meibiao and Mao, Ning and Yang, Zhao},
title = {Tumor-Educated Extracellular Vesicle-Derived LINC01116 Drives Non-Small Cell Lung Cancer Progression and Immunosuppression by Sponging miR-3614-5p to Upregulate ARHGAP1},
journal = {International Immunopharmacology},
year = {2026},
doi = {10.1016/j.intimp.2026.116347}
}
EUVIMED